US · KIDS
OrthoPediatrics Corp.
- Sector
- Healthcare · Medical - Devices
- Headquarters
- Warsaw, IN 46582
- Website
- orthopediatrics.com
Price · as of 2025-12-31
$15.63
Market cap 480.73M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $63.26 | +304.73% |
| Intrinsic Value(DCF) | $9.84 | -37.04% |
| Graham-Dodd Method(GD) | $1.67 | -89.34% |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | $0.00 | $0.00 | |||
| 2016 | $0.00 | $0.00 | |||
| 2017 | $17.50 | $82.12 | $98.69 | $0.00 | $0.00 |
| 2018 | $39.79 | $48.53 | $59.75 | $1.72 | $0.00 |
| 2019 | $44.50 | $42.67 | $73.34 | $3.25 | $0.00 |
| 2020 | $46.09 | $35.39 | $6.13 | $0.00 | $0.00 |
| 2021 | $50.17 | $52.25 | $3.30 | $3.72 | $0.00 |
| 2022 | $39.69 | $45.10 | $1.13 | $14.40 | $1.94 |
| 2023 | $27.70 | $141.85 | $1.53 | $8.31 | $0.00 |
| 2024 | $25.35 | $33.37 | $10.71 | $3.10 | $0.00 |
| 2025 | $19.22 | $63.26 | $8.14 | $1.67 | $0.00 |
AI valuation
Our deep-learning model estimates OrthoPediatrics Corp.'s (KIDS) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $63.26
- Current price
- $15.63
- AI upside
- +304.73%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$9.84
-37.04% upside
Graham-Dodd
$1.67
-89.34% upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| KIDS | OrthoPediatrics Corp. | $15.63 | 480.73M | +305% | -37% | -89% | — | -11.37 | 1.30 | 1.91 | -55.63 | -373.01 | 2.61 | 73.05% | -12.27% | -16.78% | -11.31% | -8.28% | -8.08% | 0.14 | -4.84 | 5.55 | 2.48 | -3.66 | 305.00% | 1545.00% | -6136.00% | -3.54% | -0.11 | -4.56% | 0.00% | 0.00% | 1.84% | -15.12 | -27.47 | 1.85 | 2.35 |
| BVS | Bioventus Inc. | $8.78 | 588.05M | +221% | -58% | — | — | -1890.78 | 4.06 | 1.05 | 22.83 | — | -2.28 | 67.72% | -2.09% | -5.85% | -0.20% | -2.20% | -0.04% | 2.27 | -0.31 | 1.31 | 0.80 | 7.50 | -7912.00% | 1189.00% | 37343.00% | 6.28% | 0.18 | 7.76% | 0.00% | 0.00% | 10.62% | -74.74 | 23.69 | 1.56 | 0.82 |
| CBLL | CeriBell, Inc. | $18.67 | 692.58M | +73% | +350% | — | — | -12.42 | 3.80 | 7.45 | -10.25 | — | 3.82 | 87.89% | -65.57% | -59.97% | -29.21% | -202.59% | -25.36% | 0.14 | -30.90 | 9.73 | 9.08 | 0.33 | -5693.00% | 3609.00% | 1427.00% | -6.27% | -2.13 | -144.22% | 0.00% | 0.00% | 0.00% | -9.04 | -12.70 | 5.93 | 17.63 |
| EHAB | Enhabit, Inc. | $13.61 | 689.9M | +90% | -75% | — | — | -2.78 | 0.82 | 0.41 | -11.59 | -2.98 | -0.99 | 48.71% | -11.12% | -15.09% | -25.81% | -9.68% | -11.58% | 1.09 | -2.68 | 1.53 | 1.41 | -6.47 | 9317.00% | -110.00% | 557.00% | 11.07% | 0.41 | 4.09% | 0.00% | 0.00% | 9.71% | -8.42 | 20.45 | 0.94 | 1.09 |
| EOLS | Evolus, Inc. | $4.30 | 278.73M | +754% | +521% | — | — | -16.70 | 152.52 | 3.16 | -35.41 | — | -13.07 | 68.46% | -12.92% | -18.94% | 664.86% | -75.16% | -23.92% | 23.54 | -1.84 | 2.40 | 2.14 | -1.72 | -2500.00% | 3176.00% | -4536.00% | -2.31% | -0.29 | -42.53% | 0.00% | 0.00% | 2.46% | -25.72 | -45.46 | 3.32 | -0.33 |
| LAB | Standard BioTools Inc. | $1.13 | 434.56M | +2,535% | -50% | -88% | +606% | -5.60 | 0.99 | 4.92 | -2.77 | — | 0.99 | 49.86% | -109.34% | -87.77% | -16.72% | -23.68% | -12.69% | 0.07 | -3588.65 | 4.19 | 1.86 | 0.92 | -6154.00% | -5108.00% | -4555.00% | -19.69% | -0.69 | -34.48% | 0.00% | 0.00% | 0.00% | -2.82 | -3.18 | 3.08 | 2.09 |
| RXST | RxSight, Inc. | $7.48 | 307.55M | +291% | -36% | -74% | — | — | 1.14 | 2.33 | -2.43 | — | 1.14 | 76.60% | -35.84% | -28.96% | 0.00% | -83.88% | 0.00% | 0.04 | -1204.75 | 10.95 | 9.58 | 0.22 | 3380.00% | -389.00% | -1360.00% | -6.17% | -0.59 | -33.66% | 0.00% | — | 1.44% | -2.00 | -4.98 | 0.72 | 3.16 |
| SMLR | Semler Scientific, Inc. | $20.33 | 310.75M | +321% | +54% | +196% | — | 6.57 | 1.17 | 4.78 | 11.81 | 6.92 | 16.68 | 91.55% | 37.19% | 72.65% | 27.04% | 15.50% | 25.73% | 0.00 | — | 3.59 | 3.06 | -0.41 | 9506.00% | -1744.00% | 1881.00% | 9.06% | 3.87 | 21.12% | 0.00% | 0.00% | 0.00% | 12.13 | 10.43 | 4.51 | 18.96 |
| SRDX | Surmodics, Inc. | $42.98 | 614.51M | +203% | -62% | -97% | — | -49.05 | 4.76 | 4.49 | 118.28 | -7.60 | 11.17 | 73.81% | -4.48% | -9.15% | -9.67% | -5.14% | -6.34% | 0.28 | -1.59 | 3.96 | 3.09 | -0.61 | 64545.00% | -491.00% | -14271.00% | -0.57% | 0.01 | -2.95% | 0.00% | 0.00% | 0.00% | -99.07 | -172.40 | 4.44 | 7.30 |
| TMCI | Treace Medical Concepts, … | $1.86 | 118.52M | +1,477% | -65% | — | — | -1.78 | 1.20 | 0.49 | -1.64 | -53.40 | 1.56 | 79.81% | -25.46% | -27.74% | -58.94% | -67.77% | -28.95% | 0.16 | -10.18 | 4.31 | 2.95 | -0.08 | 333.00% | 159.00% | -3953.00% | -28.08% | -0.52 | -36.90% | 0.00% | 0.00% | 52.40% | -1.30 | -2.40 | 0.33 | -0.40 |
| TOI | The Oncology Institute, I… | $2.89 | 284.32M | +772% | +1,754% | — | — | -1.01 | 14.97 | 0.14 | -2.36 | — | -2.91 | 13.73% | -15.28% | -16.44% | -174.89% | -70.35% | -27.75% | 34.31 | -8.02 | 2.15 | 1.88 | -1.37 | -2283.00% | 2133.00% | -2582.00% | -56.44% | -0.51 | -35.49% | 0.00% | 0.00% | 23.64% | -2.12 | -4.19 | 0.32 | 0.03 |
About OrthoPediatrics Corp.
OrthoPediatrics Corp., a medical device company, designs, develops, and markets anatomically appropriate implants and devices for the treatment of children with orthopedic conditions in the United States and internationally. The company offers trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products. Its products comprise PediLoc, PediPlates, cannulated screws, PediFlex nail, PediNail, PediLoc tibia, anterior cruciate ligament reconstruction systems, locking cannulated blades, locking proximal femurs, Spica Tables, RESPONSE Spine systems, Bandloc, Pediguard, Pediatric Nailing Platform, Femur system, Orthex, QuickPack, and ApiFix Mid-C system. The company serves pediatric orthopedic market, as well as pediatric orthopedic surgeons and caregivers. OrthoPediatrics Corp. was founded in 2006 and is headquartered in Warsaw, Indiana.
- CEO
- David R. Bailey
- Employees
- 562
- Beta
- 1.12
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($9.84 ÷ $15.63) − 1 = -37.04% (DCF, example).